Literature DB >> 19736620

The future therapeutic potential of histone demethylases: A critical analysis.

Gioacchino Natoli1, Giuseppe Testa, Francesca De Santa.   

Abstract

Once regarded as an irreversible modification, the methylation of histone protein tails has recently been highlighted following the identification of enzymes capable of histone demethylation in response to developmental or environmental cues. An awareness of the dynamic nature of histone modification has stimulated interest in the concept that drugs targeting histone methylation/demethylation might provide treatments for cancer, inflammation and metabolic disorders. However, epigenetic therapies that target histone demethylation are at the concept stage. Histone demethylases and their potential as therapeutic targets are discussed in this review.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19736620

Source DB:  PubMed          Journal:  Curr Opin Drug Discov Devel        ISSN: 1367-6733


  15 in total

1.  Genomic amplification and a role in drug-resistance for the KDM5A histone demethylase in breast cancer.

Authors:  Jinling Hou; Jack Wu; Alan Dombkowski; Kezhong Zhang; Andreana Holowatyj; Julie L Boerner; Zeng-Quan Yang
Journal:  Am J Transl Res       Date:  2012-07-22       Impact factor: 4.060

2.  A selective inhibitor and probe of the cellular functions of Jumonji C domain-containing histone demethylases.

Authors:  Xuelai Luo; Yongxiang Liu; Stefan Kubicek; Johanna Myllyharju; Anthony Tumber; Stanley Ng; Ka Hing Che; Jessica Podoll; Tom D Heightman; Udo Oppermann; Stuart L Schreiber; Xiang Wang
Journal:  J Am Chem Soc       Date:  2011-05-31       Impact factor: 15.419

Review 3.  Epigenetics and addiction.

Authors:  J L Cadet; M T McCoy; S Jayanthi
Journal:  Clin Pharmacol Ther       Date:  2016-02-22       Impact factor: 6.875

4.  Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer.

Authors:  Valerie Cortez; Monica Mann; Seshidhar Tekmal; Takayoshi Suzuki; Naoki Miyata; Cristian Rodriguez-Aguayo; Gabriel Lopez-Berestein; Anil K Sood; Ratna K Vadlamudi
Journal:  Breast Cancer Res       Date:  2012-07-19       Impact factor: 6.466

Review 5.  Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives.

Authors:  Federico Andreoli; Arménio Jorge Moura Barbosa; Marco Daniele Parenti; Alberto Del Rio
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.310

6.  Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia.

Authors:  Panagiotis Ntziachristos; Aristotelis Tsirigos; Pieter Van Vlierberghe; Jelena Nedjic; Thomas Trimarchi; Maria Sol Flaherty; Dolors Ferres-Marco; Vanina da Ros; Zuojian Tang; Jasmin Siegle; Patrik Asp; Michael Hadler; Isaura Rigo; Kim De Keersmaecker; Jay Patel; Tien Huynh; Filippo Utro; Sandrine Poglio; Jeremy B Samon; Elisabeth Paietta; Janis Racevskis; Jacob M Rowe; Raul Rabadan; Ross L Levine; Stuart Brown; Francoise Pflumio; Maria Dominguez; Adolfo Ferrando; Iannis Aifantis
Journal:  Nat Med       Date:  2012-02-06       Impact factor: 53.440

Review 7.  Computer-aided Molecular Design of Compounds Targeting Histone Modifying Enzymes.

Authors:  Federico Andreoli; Alberto Del Rio
Journal:  Comput Struct Biotechnol J       Date:  2015-05-07       Impact factor: 7.271

8.  A cell-permeable ester derivative of the JmjC histone demethylase inhibitor IOX1.

Authors:  Rachel Schiller; Giuseppe Scozzafava; Anthony Tumber; James R Wickens; Jacob T Bush; Ganesha Rai; Clarisse Lejeune; Hwanho Choi; Tzu-Lan Yeh; Mun Chiang Chan; Bryan T Mott; James S O McCullagh; David J Maloney; Christopher J Schofield; Akane Kawamura
Journal:  ChemMedChem       Date:  2014-02-06       Impact factor: 3.466

9.  Is JmjC oxygenase catalysis limited to demethylation?

Authors:  Richard J Hopkinson; Louise J Walport; Martin Münzel; Nathan R Rose; Tristan J Smart; Akane Kawamura; Timothy D W Claridge; Christopher J Schofield
Journal:  Angew Chem Int Ed Engl       Date:  2013-06-20       Impact factor: 15.336

10.  Pharmacological levels of Withaferin A (Withania somnifera) trigger clinically relevant anticancer effects specific to triple negative breast cancer cells.

Authors:  Katarzyna Szarc vel Szic; Ken Op de Beeck; Dariusz Ratman; An Wouters; Ilse M Beck; Ken Declerck; Karen Heyninck; Erik Fransen; Marc Bracke; Karolien De Bosscher; Filip Lardon; Guy Van Camp; Wim Vanden Berghe
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.